PATENT CLAIM ANALYSIS

Application Number: 15946355
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2019-02
Patent Classification: ["514", "305000"]

Abstract:
The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy.

Claim (Index 15):
The method of  claim 14 , wherein administration of the compound reduces GL-3 in the lysosome of the cardiomyocytes.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 91.0
- Lexical Diversity: 1.0625
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14030725', '14471958', '14776443', '15593440', '15630068']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.825044358215237
- 35 USC 102 Novelty (BERT): 0.5468751768506154
- Combined Prediction Score: 0.7972274400787749
- Mean Citation Score: 395.667856
- Max Citation Score: 544.67175
- Similarity Product: 237.5793529519066

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test